While dupilumab might affect additional aspects of atopic disease,168, 169, 170 dupilumab leads to a 20%–50% drop in serum IgE over several months,166, 171, 172, 173, 174 and >80% loss over treatment periods of 1 year or more175, 176, 177, 178 in allergic asthma, allergic rhinitis with or without nasal polyps, and atopic dermatitis patients, which fits with the notion that most IgE+ ASC are short‐lived cells in these diseases. This evidence concerns the gene IGHE and nasal cavity polyp.